Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 465 participants.
Also called NCT02874794
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 465 participants
- Sponsor
- Registry
-
NCT02874794
-
- Other papers using this trial's data
- Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial
- Changes in cardiac structure and function are associated with health-related quality of life in heart failure patients with reduced ejection fraction: Results from the EVALUATE-HF trial
- Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02874794. Randomized; triple masking; primary purpose treatment. Start 2016-08-17 (actual); primary completion 2018-12-13 (actual). Results posted on 2020-03-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
- Acronym
- EVALUATE-HF
- Condition
- Heart Failure and Reduced Ejection Fraction
- Intervention (Drug)
- LCZ696 (sacubitril/valsartan)
- Intervention (Drug)
- Enalapril
- Intervention (Drug)
- Placebo of Enalapril
- Intervention (Drug)
- Placebo of LCZ696
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct02874794- Content hash
00577625a1cac268f27f150208e5adfe0dd859ada9ac18e57e516d4b6f2811a3